Full-dose combinations of antihypertensive drugs: What has changed in experts' guidelines?


Cite item

Full Text

Abstract

The 2013 European Society of Hypertension guidelines, including treatment policy changes presupposing that one two-component combination of antihypertensive agents may be substituted for another and their full-dose combinations may be prescribed if monotherapy is ineffective, are discussed. A rationale is provided for the most effective two-component full-dose combinations of antihypertensive drugs.

Full Text

Полнодозовые комбинации антигипертензивных препаратов: что изменилось в рекомендациях экспертов?. - Аннотация. Обсуждаются рекомендации Европейского общества по артериальной гипертонии версии 2013 г., в том числе изменения в тактике лечения, предполагающие возможность смены одной двухкомпонентной комбинации антигипертензивных препаратов другой и назначение полнодозовых комбинаций при неэффективности монотерапии. Представлено обоснование наиболее эффективных двухкомпонентных полнодозовых комбинаций антигипертензивных препаратов.
×

About the authors

V V Fomin

Email: fomin_vic@mail.ru

A A Svistunov

References

  1. The ESH/ESC Task Force. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31 (7): 1281-1357.
  2. Lindholm L.H., Carlberg B., Samuelsson O. Beta blockers in primary hypertension: do age and type of beta blocker matter? J Hypertens 2006; 24 (11): 2143-2145.
  3. Dahlof B., Sever P., Poulter N.R. et al., ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
  4. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 3: 5-26.
  5. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
  6. Chapman N, Huxley R, Anderson C. et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35 (1): 116-121.
  7. Tzourio C., Anderson C., Chapman N. et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163 (9): 1069-1075.
  8. Mourad J.J., Nguyen V., Lopez-Sublet M., Waeber B. Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial. Vasc Health Risk Manag 2007; 3 (1): 173-180.
  9. Gosse P., Dubourg O., Guéret P. et al. Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. J Hum Hypertens 2002; 16 (9): 653-659.
  10. Mogensen C.E., Viberti G., Halimi S. et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071.
  11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840.
  12. Heerspink H.J., Ninomiya T., Perkovic V. et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010; 31 (23): 2888-2896.
  13. Ionescu D.D.; PREFER Investigators. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig 2009; 29 (12): 767-776.
  14. National Clinical Guidelines Centre. Hypertension. The clinical management of primary hypertension in adults. National Institute for Health and Clinical Excellence. 2011.
  15. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg. Results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18 (3): 107-113.
  16. Карпов Ю.А. от имени участников программы ФОРТИССИМО. Программа ФОРТИССИМО: преимущества фиксированной полнодозовой комбинации периндоприла аргинина и индапамида в лечении плохо контролируемой артериальной гипертонии. Кардиология 2013; 3: 38-44.
  17. Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO Trial. Adv Ther 2014; 31 (3):333-344.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies